| Literature DB >> 32461718 |
Abdelmoty Kabbash1, Rabab El Kelany1, Merfat Oreby1, Dina El Gameel1.
Abstract
Tramadol dependence became an increasing and alarming problem in the Egyptian community. Wide availability of tramadol as a pain killer and its role in the treatment of premature ejaculation may be the most apparent causes of increased magnitude of the problem among youth who believe that tramadol has a positive impact on their sexual functions. This study aimed to explore the real impact of chronic tramadol administration on sexual functions in males dependent on tramadol. The study was carried on 80 subjects (50 subjects were tramadol dependent group and 30 subjects represented the control group). Personal, family and past histories were obtained from all the participants in addition to the toxicological history from tramadol dependent group. Urine screening for tramadol was done for all cases of history of tramadol dependence then confirmation by HPLC technique to measure tramadol blood level was done. Both groups were investigated for serum testosterone and prolactin level. Curiosity (22%) and treatment of premature ejaculation (20%) were the main motives for dependence. Erectile dysfunction and decreased libido occurred in 44% and 48% of tramadol dependent group respectively. Significant increase in erectile dysfunction and decreased libido was noted as the duration of dependence increased. Additionally, significant decrease in serum testosterone level and increase in serum prolactin level as tramadol daily dose and duration increased was found. In conclusion, men who take tramadol for premature ejaculation or any other purpose must know that they are very susceptible to many sexual dysfunctions.Entities:
Keywords: dependence; prolactin; sexual dysfunction; testosterone; tramadol
Year: 2020 PMID: 32461718 PMCID: PMC7247366 DOI: 10.2478/intox-2019-0019
Source DB: PubMed Journal: Interdiscip Toxicol ISSN: 1337-6853
Types of motives for dependence in tramadol dependent group (TDG)
| Tramadol dependent group (n =50) | |||
|---|---|---|---|
| N | % | ||
| Motives for dependence | Social/financial troubles | 5 | 10 |
| Friends | 7 | 14 | |
| Pain killer | 8 | 16 | |
| Combined motives | 9 | 18 | |
| Premature ejaculation | 10 | 20 | |
| Curiosity | 11 | 22 | |
Prevalence of erectile dysfunction and decreased libido among tramadol dependent group (TDG) and control group
| TDG | Control group | χ2 | ||||
|---|---|---|---|---|---|---|
| Erectile dysfunction | Present | N | 22 | 3 | 10.089 | 0.001 |
| % | 44% | 10% | ||||
| Absent | N | 28 | 27 | |||
| % | 56% | 90% | ||||
| Decreased libido | Present | N | 24 | 5 | 7.966 | 0.005 |
| % | 48% | 16.7% | ||||
| Absent | N | 26 | 25 | |||
| % | 52% | 83.3% |
χ2: Chi-square test.
Significant at p-value <0.05.
TDG: Tramadol dependent group.
Serum testosterone and prolactin hormonal levels in tramadol dependent group (TDG) and control group
| Hormonal levels (Mean±SD) | TDG n=50 | Control group n=30 | T-test p-value |
|---|---|---|---|
| Serum testosterone (ng/dl) | 400.66±163.48 | 674.20±221.97 | 22.654 0.001 |
| Serum prolactin (ng/ml) | 22.79±8.37 | 9.45±4.04 | 21.907 0.001 |
T-test: Student t-test.
Significant at p-value <0.05.
TDG: Tramadol dependent group.
Comparison between tramadol daily dose and both testosterone and prolactin serum levels
| Hormonal Levels (Mean±SD) | Tramadol dose (mg/d) | F-test | Tukey test | ||||
|---|---|---|---|---|---|---|---|
| ≤400 | 400–1000 | >1000 | |||||
| Serum testosterone (ng/dl) | 706.29±273.40 | 374.13±246.16 | 290.92±169.27 | 7.467 | 0.002 | P1 | 0.001 |
| P2 | 0.001 | ||||||
| P3 | 0.302 | ||||||
| Serum prolactin (ng/ml) | 18.84±4.71 | 22.38±11.35 | 26.05±11.36 | 6.997 | 0.012 | P1 | 0.043 |
| P2 | 0.008 | ||||||
| P3 | 0.032 | ||||||
F. test: Analysis of variance [ANOVA].
Significant at p value <0.05.
Post hoc test (tukey test): P1: comparison between cases received tramadol doses ≤400 mg/d and cases received tramadol doses 400–1000 mg/d, P2: comparison between cases received tramadol doses ≤400 mg/d and cases received tramadol doses >1000 mg/d, P3: comparison between cases received tramadol doses 400–1000 mg/d and cases received tramadol doses >1000 mg/d.
Association between tramadol dose and presence of erectile dysfunction and decreased libido in tramadol dependent group.
| Tramadol Dose (mg/d) | χ2 | ||||||
|---|---|---|---|---|---|---|---|
| ≤400 | 400-1000 | >1000 | |||||
| Erectile dysfunction | Present | N | 1 | 15 | 6 | 2.926 | 0.232 |
| % | 14.3% | 48.4% | 50% | ||||
| Absent | N | 6 | 16 | 6 | |||
| % | 85.7% | 51.6% | 50% | ||||
| Decreased libido | Present | N | 1 | 15 | 8 | 4.865 | 0.088 |
| % | 14.3% | 48.4% | 66.7% | ||||
| Absent | N | 6 | 16 | 4 | |||
| % | 85.7% | 51.6% | 33.3% | ||||
χ2: Chi-square test.
Comparison between the duration of tramadol dependence and both testosterone and prolactin serum levels.
| Hormonal levels (Mean ±SD) | Duration of dependence | F-test | Tukey test | ||||
|---|---|---|---|---|---|---|---|
| 1-2 years | 2-5 years | >5 years | |||||
| Serum testosterone (ng/dl) | 583.60±172.71 | 404.00±198.70 | 360.35±113.75 | 4.695 | 0.021 | P1 | 0.035 |
| P2 | 0.018 | ||||||
| P3 | 0.052 | ||||||
| Serum prolactin (ng/ml) | 17.08±3.43 | 23.33±3.56 | 26.03±4.70 | 5.589 | 0.017 | P1 | 0.021 |
| P2 | 0.008 | ||||||
| P3 | 0.687 | ||||||
F test: Analysis of variance [ANOVA].
Significant at p value <0.05.
Post hoc test (tukey test): P1: comparison between cases with 1–2 years duration and cases with 2–5 years duration. P2: comparison between cases with 1–2 years duration and cases with >5 years duration. P3: comparison between cases with 2–5 years duration and cases with >5 years duration.
Association between the duration of tramadol dependence and presence of erectile dysfunction and decreased libido.
| Duration of dependence | χ2 | ||||||
|---|---|---|---|---|---|---|---|
| 1-2 years | 2-5 years | >5 years | |||||
| Erectile dysfunction | Present | N | 1 | 7 | 14 | 6.327 | 0.042 |
| % | 20% | 30.4% | 63.6% | ||||
| Absent | N | 4 | 16 | 8 | |||
| % | 80% | 69.(5% | 36.4% | ||||
| Decreased libido | Present | N | 1 | 6 | 17 | 10.859 | 0.004 |
| % | 20% | 26.1% | 77.2% | ||||
| Absent | N | 4 | 17 | 5 | |||
| % | 80% | 73.9% | 22.8% | ||||
χ2: Chi-square test.
Significant at p-value <0.05
Figure 1Correlation between tramadol blood level and serum testosterone level.
Figure 2Correlation between tramadol blood level and serum prolactin level.